Biocon Ltd Accelerates Growth with 15% YoY Revenue Increase in Q1 FY26, Launches 10th Biosimilar in Canada

Biocon Ltd commenced FY '26 on a strong note with a 15% year-on-year growth in operating revenue, led by accelerated growth in biosimilars, continued growth in CRDMO, and a steady performance in generics. The company launched the first biosimilar Aflibercept, Yesafili™, in Canada, marking its tenth biosimilar to reach commercial markets globally. Biocon Biologics secured approvals for biosimilar Denosumab from both the European Commission and U.K. MHRA, opening up a new therapeutic segment for their biosimilars business. The company also made significant strides in sustainability, receiving a Gold rating in the 2024 EcoVadis Corporate Sustainability Assessment and being recognized by Time Magazine and Statista as one of the world's most sustainable companies in 2025.